

A. PATIENT INFORMATION

Last Name

MI

First Name

DOB (DD/MM/YYYY)

Medical Record #

Biological Sex

F

M

Email

Phone

Address (Street, Unit)

City

State

Postal Code

Country

B. ORDERING PHYSICIAN INFORMATION

Distributor

Ordering Physician (full legal name)

Phone

Facility Name

Tempus Account #

Email (required for report delivery)

Fax

Facility Address (Street, Unit)

City

State

Postal Code

Country

Additional person to be copied

Form completed by

Name

Email/Fax

Facility Name

Name

Email/Fax

Facility Name

C. TESTING OPTIONS

Common test combinations

Test descriptions

Specimen required

Optional add-on tests (select all that apply)

xT (DNA) & xR (RNA):

Solid Tumor/Normal

Add xF liquid biopsy at time of order, based on the following:  
I believe it is medically necessary to order a liquid biopsy test concurrently with a solid tumor tissue test because of one or more of the following reasons: (a) guidelines support the use of testing in this disease state; (b) turnaround time for tissue result may delay a treatment decision for my patient; (c) the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision for my patient; (d) genomic heterogeneity may cause the patient's available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.

If I have not already ordered an xF test above, I opt to convert my xT solid tumor order to an xF liquid biopsy test if necessary:  
By converting immediately OR After an additional tissue request is attempted

xT: 648-gene DNA sequencing test with normal match;  
xR: whole transcriptome RNA sequencing test.

FFPE Tissue;  
Normal: Blood or Saliva

Tissue Based Add-Ons

Algorithmic Add-Ons

PD-L1 IHC<sup>1</sup>:  
22C3 DEFAULT  
28-8  
SP142  
SP263  
MMR IHC  
HER2 IHC + FISH<sup>1,2</sup>  
FOLR1 IHC FDA<sup>2</sup>  
CLDN18 IHC FDA<sup>2</sup>  
MGMT Methylation<sup>2</sup>  
1p/19q FISH<sup>2</sup>  
c-MET IHC FDA<sup>2</sup>

Immune Profile Score<sup>1</sup>  
HRD<sup>1,3</sup>  
Tumor Origin (RNA)  
DPYD<sup>1</sup>  
UGT1A1<sup>1</sup>

xT (DNA) & xR (RNA):

Solid Tumor

xT: 648-gene DNA sequencing test; xR: whole transcriptome RNA sequencing test.

FFPE Tissue

xE (DNA) & xR (RNA):

Solid Tumor/Normal

xE: over 19,000-gene whole exome DNA sequencing test with normal match;  
xR: whole transcriptome RNA sequencing test.

FFPE Tissue;  
Normal: Blood or Saliva

Individual test options

xR (RNA Only):

Solid Tumor

Whole transcriptome RNA sequencing test.

FFPE Tissue

xT (DNA Only):

Solid Tumor

648-gene DNA sequencing test.

FFPE Tissue

xF (Liquid Biopsy):

OR xF+ (Liquid Biopsy):

xF: 105-gene or xF+: 523-gene liquid biopsy test for solid tumors.

Blood (Streck)

xE (DNA Only):

Solid Tumor/Normal

xE: Over 19,000-gene whole exome DNA sequencing test with normal match.

FFPE Tissue;  
Normal: Blood or Saliva

1 See our Testing Resources website for IHC and FISH tests ordered by cancer type, and Algorithmic Add-On logistics.

2 Powered by NeoGenomics.

3 Normal sample is required for ovarian and breast cancers.

Monitoring—Must select only one testing cadence. \*Standing orders are for one year unless # of draws is indicated. See reverse for details about the Tempus Default Cadence.

xM: Single test Every 3 months\* Every 6 months\* Tempus Default Cadence\*

xM: Tumor-naïve minimal residual disease (MRD) assay for CRC patients; Blood (Streck)

# of Draws Date of curative intent surgery

If the first test result is MRD+, xM also includes a xF test result. Do not order xF even if the first xM test result is MRD+

D. SPECIMEN RETRIEVAL See Tempus' specimen guidelines for collection instructions and further details.

FFPE Tissue

Option 1:  
Specific specimen requested

Option 2:  
Let the submitting pathologist choose specimen

Option 3:  
Biopsy to be scheduled for:

Pathology Lab (Name, City)

Case Number

Block #

Date of Collection

Blood

Saliva

Sample previously submitted

Send saliva kit to patient

Date of Collection:

Date of Collection:

E. CURRENT DIAGNOSIS

Breast NSCLC Pancreatic Other:

Primary ICD-10 Codes (C & D codes only)

Stage I III Other:

Colorectal Ovarian Prostate

II IV

Disease Status (select all that apply):  
Metastatic Relapse Other:  
Refractory Recurrent

Has the patient had any type of transplant?  
No  
Yes —Type:

Attachments  
Copy of patient's progress notes and/or medical records.  
Copy of recent pathology report.

F. BILLING INFORMATION

Primary Insurance Plan Name

Policy #

Authorisation #

Policy Holder Name

Policy Holder DOB

Patient Relationship to Policy Holder  
Self Spouse Child Other:

Bill Type:  
Insurance Hospital/Institution Self pay/International

G. PHYSICIAN SIGNATURE AND CONSENT

I certify that the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s). My signature certifies medical necessity of the test(s) (including that the test results will inform the treatment plan) and further certifies that I am authorized to order the test(s) and that the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims (if applicable); and (c) collect, use, and retain samples and information obtained from the patient, all in accordance with the Tempus Consent to Genomic Testing form signed by the patient.

Ordering Physician Signature

Printed Name (full legal name)

Today's Date (DD/MM/YYYY)

Find the most recent documents at tempus.com/resources/document-library/  
2025-06

PAGE 1 / 1

Phone: 800.739.4137 | Fax: 800.893.0276 | support@tempus.com  
600 West Chicago Avenue Suite 510, Chicago, IL 60654 | tempus.com